Chen Yinan, Zhu Zhenggang, Yu Yingyan
Department of Surgery, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Ruijin er Road, No. 197, 200025, Shanghai, China.
Tumour Biol. 2014 Oct;35(10):9469-77. doi: 10.1007/s13277-014-2439-2. Epub 2014 Aug 14.
Enzyme-linked immuno-sorbent assay (ELISA) is widely used for biomarker detection. A good biomarker can distinguish patients from healthy or benign diseases. However, the ELISA method is not suitable for small molecule or trace substance detection. Along with the development of new technologies, an increasing level of biomaterials, especially small molecules, will be identified as novel biomarkers. Quantitative immuno-PCR, chromatography-mass spectrometry, and nucleic acid aptamer are emerging methodologies for detection of small molecule biomarkers, even in living cells. In this review, we focus on these novel technologies and their potential for small molecule biomarkers and living cell analysis.
酶联免疫吸附测定（ELISA）被广泛用于生物标志物检测。一种良好的生物标志物能够区分患者与健康个体或患有良性疾病的人。然而，ELISA方法不适用于小分子或痕量物质的检测。随着新技术的发展，越来越多的生物材料，尤其是小分子，将被鉴定为新型生物标志物。定量免疫PCR、色谱-质谱联用以及核酸适配体是用于检测小分子生物标志物的新兴方法，甚至可用于活细胞中的检测。在本综述中，我们重点关注这些新技术及其在小分子生物标志物和活细胞分析方面的潜力。
